Trial Profile
An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With Elaprase in Patients With Hunter Syndrome and Cognitive Impairment
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Idursulfase (Primary) ; Idursulfase
- Indications Cognition disorders; Mucopolysaccharidosis II
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Shire; Takeda
- 19 Dec 2023 Planned End Date changed from 15 Dec 2023 to 29 Mar 2024.
- 19 Dec 2023 Planned primary completion date changed from 15 Dec 2023 to 29 Mar 2024.
- 17 Jul 2023 Planned End Date changed from 30 Jun 2023 to 15 Dec 2023.